Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

Is this the dose for you?: the role of modeling.

Huang SM, Bhattaram A, Mehrotra N, Wang Y.

Clin Pharmacol Ther. 2013 Feb;93(2):159-62. doi: 10.1038/clpt.2012.228. Epub 2012 Nov 19.

PMID:
23281423
[PubMed - indexed for MEDLINE]
2.

Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.

Ettenger R, Schmouder R, Kovarik JM, Bastien MC, Hoyer PF.

Pediatr Transplant. 2011 Jun;15(4):406-13. doi: 10.1111/j.1399-3046.2011.01498.x.

PMID:
21585629
[PubMed - indexed for MEDLINE]
3.

Oral fingolimod (gilenya) for multiple sclerosis.

[No authors listed]

Med Lett Drugs Ther. 2010 Dec 29;52(1353-1354):98-9. Review. No abstract available.

PMID:
21344782
[PubMed - indexed for MEDLINE]
4.

Fingolimod for multiple sclerosis.

[No authors listed]

Drug Ther Bull. 2012 Feb;50(2):18-20. doi: 10.1136/dtb.2012.02.0086.

PMID:
22329953
[PubMed - indexed for MEDLINE]
5.

Delayed fingolimod-associated asystole.

Espinosa PS, Berger JR.

Mult Scler. 2011 Nov;17(11):1387-9. doi: 10.1177/1352458511410344. Epub 2011 Jun 7.

PMID:
21652609
[PubMed - indexed for MEDLINE]
6.

Trial watch: Phase III promise for oral multiple sclerosis therapy.

[No authors listed]

Nat Rev Drug Discov. 2009 Feb;8(2):98. doi: 10.1038/nrd2821. No abstract available.

PMID:
19180099
[PubMed - indexed for MEDLINE]
7.

Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.

Tanaka M, Park K, Tanaka K.

Mult Scler. 2013 Aug;19(9):1244-5. doi: 10.1177/1352458512472750. Epub 2013 Jan 15. No abstract available.

PMID:
23322501
[PubMed - indexed for MEDLINE]
8.

Progressive multifocal leukoencephalopathy in a patient taking the MS pill Gilenya.

[No authors listed]

Clin Infect Dis. 2013 Oct;57(8):ii. No abstract available.

PMID:
24195115
[PubMed - indexed for MEDLINE]
9.

[2012: Update on diagnosis and treatment of multiple sclerosis].

Havla J, Kümpfel T, Hohlfeld R.

Dtsch Med Wochenschr. 2012 Apr;137(17):894-9. doi: 10.1055/s-0032-1304927. Epub 2012 Apr 10. Review. German. No abstract available. Erratum in: Dtsch Med Wochenschr. 2012 May;137(20):1072.

PMID:
22492476
[PubMed - indexed for MEDLINE]
10.

Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.

Singer B, Ross AP, Tobias K.

Int J Clin Pract. 2011 Aug;65(8):887-95. doi: 10.1111/j.1742-1241.2011.02721.x. Epub 2011 Jun 16. Review.

PMID:
21679286
[PubMed - indexed for MEDLINE]
11.

FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study.

Mulgaonkar S, Tedesco H, Oppenheimer F, Walker R, Kunzendorf U, Russ G, Knoflach A, Patel Y, Ferguson R; FTYA121 study group.

Am J Transplant. 2006 Aug;6(8):1848-57. Epub 2006 Jun 12. Erratum in: Am J Transplant. 2006 Dec;6(12):3044.

PMID:
16771816
[PubMed - indexed for MEDLINE]
Free Article
12.
13.

[A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].

Popova NF.

Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):110-3. Russian. No abstract available.

PMID:
21916166
[PubMed - indexed for MEDLINE]
14.

[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].

Széplaki G, Merkely B.

Ideggyogy Sz. 2012 Nov 30;65(11-12):369-76. Review. Hungarian.

PMID:
23289171
[PubMed - indexed for MEDLINE]
15.

Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.

Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S, Gonwa TA, Skerjanec A, Schmouder RL, Chodoff L.

Transplantation. 2003 Oct 15;76(7):1079-84.

PMID:
14557756
[PubMed - indexed for MEDLINE]
16.

Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression.

Bech P, Tanghøj P, Andersen HF, Overø K.

Psychopharmacology (Berl). 2002 Aug;163(1):20-5. Epub 2002 Jul 3.

PMID:
12185396
[PubMed - indexed for MEDLINE]
17.

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results.

Comi G, O'Connor P, Montalban X, Antel J, Radue EW, Karlsson G, Pohlmann H, Aradhye S, Kappos L; FTY720D2201 Study Group.

Mult Scler. 2010 Feb;16(2):197-207. doi: 10.1177/1352458509357065. Epub 2009 Dec 22.

PMID:
20028707
[PubMed - indexed for MEDLINE]
18.

FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship.

Skerjanec A, Tedesco H, Neumayer HH, Cole E, Budde K, Hsu CH, Schmouder R.

J Clin Pharmacol. 2005 Nov;45(11):1268-78.

PMID:
16239360
[PubMed - indexed for MEDLINE]
19.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
[PubMed - indexed for MEDLINE]
20.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group.

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

PMID:
20089952
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk